Overwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer’s Disease (AD); Underwhelming Evidence against
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
This review describes investigations of specific topics that lie within the general subject of HSV1’s role in AD/dementia, published in the last couple of years. They include studies on the following: relationship of HSV1 to AD using neural stem cells; the apparent protective effects of treatment of HSV1 infection or of VZV infection with antivirals prior to the onset of dementia; the putative involvement of VZV in AD/dementia; the possible role of human herpes virus 6 (HHV6) in AD; the seemingly reduced risk of dementia after vaccination with diverse types of vaccine, and the association shown in some vaccine studies with reduced frequency of HSV1 reactivation; anti-HSV serum antibodies supporting the linkage of HSV1 in brain with AD in APOE-ε4 carriers, and the association between APOE and cognition, and association of APOE and infection with AD/dementia. The conclusions are that there is now overwhelming evidence for HSV1’s role—probably causal—in AD, when it is present in brain of APOE-ε4 carriers, and that further investigations should be made on possible prevention of the disease by vaccination, or by prolonged antiviral treatment of HSV1 infection in APOE-ε4 carriers, before disease onset.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurologic features in severe SARS-CoV-2 infection
Helms, J., Kremer, S., Merdji, H., Clere-Jehl, R., Schenck, M., Kummerlen, C., Collange, O., Boulay, C., Fafi-Kremer, S., Ohana, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2008597 · Cited by 2,674
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281 · cited 2×
“Other evidence supporting the possibility that HSV1-specific antibodies have a protective effect against AD development includes the fact that AD incidence increases with age—probably because of the decline of the immune responses with age; also, age-dependent blood-brain barrier (BBB) injuries, although detected in n…”
BackgroundReadhead, B., Haure-Mirande, J.-V., Funk, C. C., Richards, M. A., Shannon, P., Haroutunian, V., Sano, M., Liang, W. S., Beckmann, N. D., Price, N. D., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.05.023 · Cited by 708
Heneka, M. T., Golenbock, D., Latz, E., Morgan, D., & Brown, R. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00640-3 · Cited by 555 · cited 1×
“[18] have commented on the possible long-term effects of COVID-19, describing the neurological deficits of infection with Sars-CoV-2 in many patients.”
BackgroundNon-specific effects of BCG vaccine on viral infections
Moorlag, S. J. C. F. M., Arts, R. J. W., van Crevel, R., & Netea, M. G. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.020 · Cited by 479
APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort
Kuo, C.-L., Pilling, L. C., Atkins, J. L., Masoli, J. A. H., Delgado, J., Kuchel, G. A., & Melzer, D. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glaa131 · Cited by 388
Defective mitophagy in Alzheimer’s disease
Pradeepkiran, J. A., & Reddy, P. H. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101191 · Cited by 367
Tzeng, N.-S., Chung, C.-H., Lin, F.-H., Chiang, C.-P., Yeh, C.-B., Huang, S.-Y., Lu, R.-B., Chang, H.-A., Kao, Y.-C., Yeh, H.-W., et al. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0611-x · Cited by 356 · cited 2×
“Further, their comparison with the Taiwanese study of Tzeng et al. (2018) was not valid, since the latter compared HSV1-infected carriers of (almost certainly) APOE-ε4 with people uninfected with the virus”
BackgroundResultDe Chiara, G., Piacentini, R., Fabiani, M., Mastrodonato, A., Marcocci, M. E., Limongi, D., Napoletani, G., Protto, V., Coluccio, P., Celestino, I., et al. (2019) · PLOS Pathogens · doi:10.1371/journal.ppat.1007617 · Cited by 266 · cited 1×
“[71] investigated oxidative damage in the mouse model set up by the same group [72], in which multiple HSV1 reactivations were achieved by thermal stress.”
BackgroundCorroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease
Itzhaki, R. F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00324 · Cited by 256
Self-citationLetenneur, L., Pérès, K., Fleury, H., Garrigue, I., Barberger-Gateau, P., Helmer, C., Orgogozo, J.-M., Gauthier, S., & Dartigues, J.-F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003637 · Cited by 252 · cited 1×
“[55] surveyed a group of people aged 65 over a 14-year period and found, using serum anti-HSV1 IgM as a marker of recent HSV1 reactivation in the PNS, that those who experienced HSV1 reactivation had an increased risk of developing AD”
BackgroundA 3D human brain–like tissue model of herpes-induced Alzheimer’s disease
Cairns, D. M., Rouleau, N., Parker, R. N., Walsh, K. G., Gehrke, L., & Kaplan, D. L. (2020) · Science Advances · doi:10.1126/sciadv.aay8828 · Cited by 247 · cited 2×
“[5] strongly supports the use of antiviral treatment for AD patients, and a clinical trial of VCV to treat AD patients is ongoing at Columbia university.”
BackgroundNew approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226 · cited 1×
“[8], is yielding encouraging results: a phase 2 trial of GV971, a compound derived from brown algae which consists of polysaccharides—linear sodium oligomannate molecules—of a range of sizes.”
ResultXiao, S., Chan, P., Wang, T., Hong, Z., Wang, S., Kuang, W., He, J., Pan, X., Zhou, Y., Ji, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00795-7 · Cited by 224
Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease
Linard, M., Letenneur, L., Garrigue, I., Doize, A., Dartigues, J., & Helmer, C. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12008 · Cited by 152
Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study
Chen, V. C.-H., Wu, S.-I., Huang, K.-Y., Yang, Y.-H., Kuo, T.-Y., Liang, H.-Y., Huang, K.-L., & Gossop, M. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11312 · Cited by 142 · cited 2×
“[26] compared herpes zoster (HZ—shingles) patients with controls and found there was a slightly increased risk associated with HZ (HR (Hazard ratio) 1.”
BackgroundResult3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Human Herpesvirus 6 Detection in Alzheimer’s Disease Cases and Controls across Multiple Cohorts
Allnutt, M. A., Johnson, K., Bennett, D. A., Connor, S. M., Troncoso, J. C., Pletnikova, O., Albert, M. S., Resnick, S. M., Scholz, S. W., De Jager, P. L., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.031 · Cited by 119
Increased risk of dementia following herpes zoster ophthalmicus
Tsai, M.-C., Cheng, W.-L., Sheu, J.-J., Huang, C.-C., Shia, B.-C., Kao, L.-T., & Lin, H.-C. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188490 · Cited by 107 · cited 1×
“supports the four previous findings [26,28,29,31] in showing that VZV, like HSV1, confers a risk of dementia (supported further by epidemiological and serological research on VZV by the present author and her colleagues [32,33].”
ResultLopatko Lindman, K., Hemmingsson, E., Weidung, B., Brännström, J., Josefsson, M., Olsson, J., Elgh, F., Nordström, P., & Lövheim, H. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12119 · Cited by 99
Bae, S., Yun, S.-C., Kim, M.-C., Yoon, W., Lim, J. S., Lee, S.-O., Choi, S.-H., Kim, Y. S., Woo, J. H., Kim, S. Y., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01157-4 · Cited by 94
Protto, V., Tramutola, A., Fabiani, M., Marcocci, M. E., Napoletani, G., Iavarone, F., Vincenzoni, F., Castagnola, M., Perluigi, M., Di Domenico, F., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8070972 · Cited by 36 · cited 1×
“[71] investigated oxidative damage in the mouse model set up by the same group [72], in which multiple HSV1 reactivations were achieved by thermal stress.”
BackgroundMekli, K., Lophatananon, A., Cant, R., Burns, A., Dobson, C. B., Itzhaki, R. F., & Muir, K. R. (2022) · PLOS ONE · doi:10.1371/journal.pone.0274872 · Cited by 25
Self-citation
Cited by
Cruchaga, C., Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Ali, M., Beric, A., Gorijala, P., Kohlfeld, P., et al. (2023) · doi:10.21203/rs.3.rs-2814616/v1 · Cited by 112
Western, D., Timsina, J., Wang, L., Wang, C., Yang, C., Phillips, B., Wang, Y., Liu, M., Ali, M., Beric, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01972-8 · Cited by 111
Vestin, E., Boström, G., Olsson, J., Elgh, F., Lind, L., Kilander, L., Lövheim, H., & Weidung, B. (2024) · Journal of Alzheimer’s Disease · doi:10.3233/jad-230718 · Cited by 44
“Symptomatic reactivation may be overrepresented among APOE (cid:2) 4 carriers and these factors may interfere with risk assessment [22–24].”
BackgroundWennberg, A. M., Maher, B. S., Rabinowitz, J. A., Holingue, C., Felder, W. R., Wells, J. L., Munro, C. A., Lyketsos, C. G., Eaton, W. W., Walker, K. A., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13070 · Cited by 19
“…mounting evidence suggests that two neurotropic members of the Herpesviridae family, HSV-1 and VZV, are associated with increased risk of AD 38,39 ; indeed, a study of over 8,000 people in Taiwan showed that those who had documented active HSV infections were 2.5 times more likely to have…”
BackgroundInfluentialHow viral infections cause neuronal dysfunction: a focus on the role of microglia and astrocytes
Hosseini, S., & Korte, M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220771 · Cited by 17
Metadata
- Authors
- Itzhaki, R. F.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-06-21
- Volume
- 9
- Issue
- 6
- Pages
- 679
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W3175338347
- Cited by
- 123
- References
- 24
- FWCI
- 10.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.